Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subjects With Epilepsy

Trial Profile

Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subjects With Epilepsy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Topiramate (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 12 May 2016 Treatment arms has changed from 1 to 4, duration has changed from 22-39 days to 1-14 days, and different dosage of the drug TPM XR has been added.
    • 11 Jul 2012 Actual end date (June 2012) added as reported by ClinicalTrials.gov.
    • 01 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top